| Name | Azelnidipine |
| Description | Azelnidipine (UR-12592) is a dihydropyridine used as calcium channel blocker. |
| In vivo | Studies indicate that Azelnidipine, as a new-generation calcium channel blocker, can treat hypertension regardless of the patient's risk for ischemic heart disease. This novel, long-acting calcium channel blocker exhibits unique pharmacological properties, such as a slower heart rate and high affinity for vascular tissue, distinguishing it from other calcium channel blockers. Additionally, the high lipophilicity of Azelnidipine allows it to remain active in the vascular wall even after being cleared from the bloodstream. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | H2O : < 1 mg/mL (insoluble or slightly soluble)
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 4 mg/mL (6.87 mM), Sonication is recommended.
Ethanol : 7 mg/mL (12.01 mM), Sonication is recommended.
DMSO : 250 mg/mL (429.07 mM), Sonication is recommended.
|
| Keywords | UR12592 | UR 12592 | Inhibitor | inhibit | CS-905 | CS905 | CalciumChannel | Calcium Channel | Ca2+ channels | Ca channels | Azelnidipine |
| Inhibitors Related | Quadrol | Tricaine methanesulfonate | Nisoldipine | 2,4,6-Tri-tert-butylphenol | Chlorocresol | L-Ascorbic acid | L-Phenylalanine | L-Ascorbic acid sodium salt | 1-Octanol | 2-Nitrobenzoic acid | Magnesium Chloride Hexahydrate | Magnesium sulfate |
| Related Compound Libraries | Bioactive Compound Library | Pain-Related Compound Library | Membrane Protein-targeted Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Neuroprotective Compound Library | Anti-Cancer Approved Drug Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Ion Channel Targeted Library | Anti-Cancer Drug Library |
United States
